evidoria

← Back to browse

Good practice Imported

Biopolis — Singapore's Biomedical R&D Cluster

Singapore · Singapore · See the Singapore profile · See the Singapore profile

Evidence: Observational / pre–post Top 42% 71/100 · Ask Evidence Copilot about this practice

Singapore's biomedical hub at one-north — 5 A*STAR research institutes co-located with 40+ private pharma tenants, growing biomedical manufacturing output from SGD 6 B (2000) to SGD 39 B (2023) and employment from 6,000 to 26,000+.

6 SGD billion
Biomedical manufacturing output (2000)
29.4 SGD billion
Biomedical manufacturing output (2012)
39 SGD billion
Biomedical manufacturing output (2023)
15.3 SGD billion (25.5% of total manufacturing value)
Value-added share of manufacturing output
6,000
Employment in biomedical sciences (2000)
15,700
Employment in biomedical sciences (2012)
26,481
Employment in biopharmaceutical manufacturing (2023)
25 %
Share of Singapore biotechs that are A*STAR spinoffs
500 S$ million
Government investment to build Biopolis
18.5 hectares
Biopolis campus area
3.5 million sq ft
Biopolis floor area (by 2022)
Biopolis — Singapore's Biomedical R&D Cluster

Details

Maturity
Established
Promoter
JTC Corporation / Agency for Science, Technology and Research (A*STAR)
Period
2003–present
Keywords
biomedical sciences, pharmaceuticals, life sciences, medtech

Context

Biopolis is an 18.5-hectare biomedical R&D cluster in Singapore's one-north precinct, opened in October 2003 after a S$500 million government investment, built as the physical centrepiece of Singapore's strategy to build biomedical sciences into a fourth economic pillar. It is run through A*STAR (five co-located research institutes: GIS, IBN, BII, IMCB, and Bioprocessing Technology Institute) and JTC Corporation, with private tenants including Novartis, GlaxoSmithKline and Procter & Gamble sharing campus buildings under a deliberate co-location model.

Activities

The cluster expanded across six phases to over 3.5 million square feet by 2022, and its flagship public-private partnership, the Novartis Institute for Tropical Diseases (set up with Singapore's EDB in 2002), exemplifies the co-location model that pairs public research institutes with pharmaceutical tenants such as Novartis (USD 200 million over five years) and Procter & Gamble (USD 250 million innovation centre).

Results

Biomedical manufacturing output grew nearly fivefold from SGD 6 billion in 2000 to SGD 29.4 billion by 2012, reaching SGD 39 billion by 2023; employment grew 2.5 times from 6,000 to 15,700 by 2012, and reached 26,481 in biopharmaceutical manufacturing alone by 2023. About a quarter of all biotechs currently operating in Singapore are A*STAR spinoffs.

Conclusions

Independent academic reviews caution that spin-off commercialisation has been slower than anticipated, with only a handful of novel diagnostics discovered at Biopolis reaching market, and that the cluster has historically depended on internationally recruited scientists rather than home-grown talent.

Implementation
Indicative cost
Very high (> €5M) — Built with a S$500 million government investment completed in under 20 months, then expanded across six phases to over 3.5 million square feet by 2022, implying a very high cumulative infrastructure cost.
Time to results
Long (> 3 years) — Opened in October 2003 and has operated continuously for over two decades, with output and employment growth tracked through 2023.
Staffing & skills
A*STAR (Agency for Science, Technology and Research) — five co-located research institutes (GIS, IBN, BII, IMCB, Bioprocessing Technology Institute), JTC Corporation (state industrial landlord/developer)

Conditions for success

  • Deliberate co-location of public research institutes and private pharmaceutical tenants (Novartis, GlaxoSmithKline, Procter & Gamble) within shared campus buildings.
  • Structured public-private partnerships, such as the Novartis Institute for Tropical Diseases set up with Singapore's EDB.
  • Sustained multi-phase government investment expanding the campus across six phases to over 3.5 million square feet by 2022.

Common failure modes

  • Spin-off commercialisation has been slower than anticipated, with only a handful of novel diagnostics discovered at Biopolis reaching market.
  • Historical dependence on internationally recruited scientists rather than home-grown talent.

Where it fits

Governance type
national government agency / statutory board
Scale
national flagship cluster (18.5 hectares, 3.5M+ sq ft)
Income level
high-income

Commonly funded by

National / regional programmes

Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.

Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.

Data sources

Where this practice's information was retrieved from, and when.

Attachments

Similar practices you may find useful

★ 71

Ideon Science Park (Lund)

Sweden

Sweden's oldest and largest science park, founded in Lund in 1983 by the university, region and city, is where Ericsson …